Early-stage venture · Life-science infrastructure
Backing biology
of new frontiers.
A USD $15M fund backing research advancing frontiers of biology — in the area of most critical global biology infrastructure. We leverage 20+ years of operating experience to turn rigorous science into durable enterprises.
Where we invest.
- 01
Systems biology
Platform science with the ability to progress broad-spectrum solutions across living systems.
- 02
Synthetic biology
Engineering biological processes into industrial-scale infrastructure and new modalities.
- 03
Genetics
Dark DNA, non-coding RNA, and the unread code that defines the next generation of therapeutics.
AMR is projected to cause 10 million deaths annually by 2050, with global economic costs estimated to surpass $100 trillion.
Less than 2% of venture capital globally goes into companies working on antimicrobial resistance — and over 80% of AMR-focused funding targets clinical-stage companies, leaving a critical gap in the preclinical science where breakthroughs begin.
Key details.
- Fund
- USD $15M
- Stage
- Pre-seed · Seed
- Portfolio
- Up to 10 companies
- Horizon
- 10 years
- Geography
- Agnostic
- Focus
- AMR · ncRNA · Biosecurity